vs
Side-by-side financial comparison of Hologic (HOLX) and Construction Partners, Inc. (ROAD). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $769.2M, roughly 1.4× Construction Partners, Inc.). Hologic runs the higher net margin — 17.1% vs 1.2%, a 15.9% gap on every dollar of revenue. On growth, Construction Partners, Inc. posted the faster year-over-year revenue change (34.6% vs 2.5%). Over the past eight quarters, Construction Partners, Inc.'s revenue compounded faster (21.9% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Alexander Construction Company was a Palm Springs, California, residential development company that built over 2,200 houses in the Coachella Valley of Riverside County, California, between 1955 and 1965.
HOLX vs ROAD — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $769.2M |
| Net Profit | $179.1M | $9.2M |
| Gross Margin | 56.0% | 12.9% |
| Operating Margin | 22.6% | 4.9% |
| Net Margin | 17.1% | 1.2% |
| Revenue YoY | 2.5% | 34.6% |
| Net Profit YoY | -10.9% | 688.7% |
| EPS (diluted) | $0.79 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $769.2M | ||
| Q4 25 | $1.0B | $809.5M | ||
| Q3 25 | $1.0B | $899.8M | ||
| Q2 25 | $1.0B | $779.3M | ||
| Q1 25 | $1.0B | $571.6M | ||
| Q4 24 | $1.0B | $561.6M | ||
| Q3 24 | $988.0M | $538.2M | ||
| Q2 24 | $1.0B | $517.8M |
| Q1 26 | — | $9.2M | ||
| Q4 25 | $179.1M | $17.2M | ||
| Q3 25 | $187.2M | $56.6M | ||
| Q2 25 | $194.9M | $44.0M | ||
| Q1 25 | $-17.4M | $4.2M | ||
| Q4 24 | $201.0M | $-3.1M | ||
| Q3 24 | $178.6M | $29.3M | ||
| Q2 24 | $194.5M | $30.9M |
| Q1 26 | — | 12.9% | ||
| Q4 25 | 56.0% | 15.0% | ||
| Q3 25 | 55.6% | 17.7% | ||
| Q2 25 | 56.3% | 16.9% | ||
| Q1 25 | 37.5% | 12.5% | ||
| Q4 24 | 56.8% | 13.6% | ||
| Q3 24 | 56.4% | 15.6% | ||
| Q2 24 | 55.4% | 16.1% |
| Q1 26 | — | 4.9% | ||
| Q4 25 | 22.6% | 6.2% | ||
| Q3 25 | 22.6% | 11.2% | ||
| Q2 25 | 24.9% | 10.6% | ||
| Q1 25 | -0.7% | 4.8% | ||
| Q4 24 | 22.5% | 2.5% | ||
| Q3 24 | 23.3% | 8.5% | ||
| Q2 24 | 24.1% | 8.8% |
| Q1 26 | — | 1.2% | ||
| Q4 25 | 17.1% | 2.1% | ||
| Q3 25 | 17.8% | 6.3% | ||
| Q2 25 | 19.0% | 5.7% | ||
| Q1 25 | -1.7% | 0.7% | ||
| Q4 24 | 19.7% | -0.5% | ||
| Q3 24 | 18.1% | 5.4% | ||
| Q2 24 | 19.2% | 6.0% |
| Q1 26 | — | $0.16 | ||
| Q4 25 | $0.79 | $0.31 | ||
| Q3 25 | $0.84 | $1.03 | ||
| Q2 25 | $0.86 | $0.79 | ||
| Q1 25 | $-0.08 | $0.08 | ||
| Q4 24 | $0.87 | $-0.06 | ||
| Q3 24 | $0.75 | $0.55 | ||
| Q2 24 | $0.82 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $76.9M |
| Total DebtLower is stronger | $2.5B | $38.5M |
| Stockholders' EquityBook value | $5.2B | $979.4M |
| Total Assets | $9.2B | $3.4B |
| Debt / EquityLower = less leverage | 0.48× | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $76.9M | ||
| Q4 25 | $2.4B | $104.1M | ||
| Q3 25 | $2.2B | $156.1M | ||
| Q2 25 | $1.9B | $114.3M | ||
| Q1 25 | $1.6B | $101.9M | ||
| Q4 24 | $2.0B | $132.5M | ||
| Q3 24 | $2.3B | $74.7M | ||
| Q2 24 | $2.4B | $56.3M |
| Q1 26 | — | $38.5M | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | $1.6B | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | $515.0M | ||
| Q2 24 | $2.5B | — |
| Q1 26 | — | $979.4M | ||
| Q4 25 | $5.2B | $969.1M | ||
| Q3 25 | $5.0B | $912.0M | ||
| Q2 25 | $4.8B | $853.3M | ||
| Q1 25 | $4.6B | $807.9M | ||
| Q4 24 | $4.8B | $811.1M | ||
| Q3 24 | $5.1B | $573.7M | ||
| Q2 24 | $5.0B | $552.9M |
| Q1 26 | — | $3.4B | ||
| Q4 25 | $9.2B | $3.4B | ||
| Q3 25 | $9.0B | $3.2B | ||
| Q2 25 | $8.8B | $2.9B | ||
| Q1 25 | $8.5B | $2.8B | ||
| Q4 24 | $8.7B | $2.6B | ||
| Q3 24 | $9.2B | $1.5B | ||
| Q2 24 | $8.9B | $1.4B |
| Q1 26 | — | 0.04× | ||
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | 1.78× | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | 0.90× | ||
| Q2 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $147.8M |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | 16.10× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $147.8M | ||
| Q4 25 | $229.9M | $82.6M | ||
| Q3 25 | $355.1M | $112.0M | ||
| Q2 25 | $343.3M | $83.0M | ||
| Q1 25 | $169.4M | $55.6M | ||
| Q4 24 | $189.3M | $40.7M | ||
| Q3 24 | $367.0M | $95.9M | ||
| Q2 24 | $405.8M | $34.6M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $47.1M | ||
| Q3 25 | $341.4M | $78.9M | ||
| Q2 25 | $330.5M | $46.4M | ||
| Q1 25 | $153.9M | $14.2M | ||
| Q4 24 | $172.5M | $13.8M | ||
| Q3 24 | $350.6M | $78.4M | ||
| Q2 24 | $385.3M | $19.7M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 5.8% | ||
| Q3 25 | 32.5% | 8.8% | ||
| Q2 25 | 32.3% | 5.9% | ||
| Q1 25 | 15.3% | 2.5% | ||
| Q4 24 | 16.9% | 2.5% | ||
| Q3 24 | 35.5% | 14.6% | ||
| Q2 24 | 38.1% | 3.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 4.4% | ||
| Q3 25 | 1.3% | 3.7% | ||
| Q2 25 | 1.3% | 4.7% | ||
| Q1 25 | 1.5% | 7.2% | ||
| Q4 24 | 1.6% | 4.8% | ||
| Q3 24 | 1.7% | 3.3% | ||
| Q2 24 | 2.0% | 2.9% |
| Q1 26 | — | 16.10× | ||
| Q4 25 | 1.28× | 4.80× | ||
| Q3 25 | 1.90× | 1.98× | ||
| Q2 25 | 1.76× | 1.88× | ||
| Q1 25 | — | 13.20× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | 3.27× | ||
| Q2 24 | 2.09× | 1.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
ROAD
Segment breakdown not available.
